Please assess the completion status of the following clinical trial:

Trial Title: GS-5734 to Assess the Antiviral Activity, Longer-Term Clearance of Ebola Virus, and Safety in Male Ebola Survivors With Evidence of Ebola Virus Persistence in Semen

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: QUADRUPLE
- Phase: PHASE2
- Number of Arms: 2.0

Eligibility Criteria:
* INCLUSION CRITERIA:~Individuals must meet all of the following criteria to be eligible for study participation:~* Men more than or equal to 18 years of age.~* One of two semen samples with Ebola virus RNA detection (defined as a positive PCR for NP or GP using the GeneXpert assay within 42 days prior to randomization).~* Willingness to be available for study evaluations for 6 months.~* Willingness to allow storage of biological samples.~* Willingness to be followed by a Participant Tracker.~* Willingness to refrain from alcohol consumption for study days -7 to 14.~* Willingness to comply with MOH \& CDC guidance on using a condom for sexual activity and at least through week 24 of the study.~EXCLUSION CRITERIA:~Individuals meeting any of the following criteria will be excluded from study participation:~* Estimated glomerular filtration rate less than 60 mL/min/1.73m\^2~* History of significant renal disease~* History of significant liver disease~* Evidence of liver disease on physical exam such as ascites~* Aspartate transaminase (AST) or alanine transaminase (ALT), greater than the upper limit of normal, a prothrombin time 1.1 times greater than the upper limits of normal, normal, or a total bilirubin \> 1.5 times the upper limits of normal(per Division of Acquired Immunodeficiency Syndrome (DAIDS) toxicity tables version 2.0 Nov. 2014).~* Presence of Grade 2 or higher abnormalities for: low hemoglobin, low white blood count (WBC), low platelets, or low or high potassium (per DAIDS toxicity tables version 2.0 Nov. 2014).~* Presence of greater than Grade 2 abnormalities for low or high sodium (per DAIDS toxicity tables version 2.0 Nov. 2014).~* Any condition that, in the opinion of the investigator, would compromise the safety of the study subject or staff, or would prevent proper conduct of the study.

- Gender: MALE
- Minimum Age: 18 Years
- Maximum Age: 99 Years
- Healthy Volunteers: f

Study Arms:
- GS-5734 100mg given intravenously daily for 5 days (Type: ACTIVE_COMPARATOR): Male Ebola survivors with persistent Ebola virus in their semen were given GS-5734 100mg intravenously daily for 5 days
- Normal saline intravenously for 5 days (Type: PLACEBO_COMPARATOR): Male Ebola survivors with persistent Ebola virus in their semen were given normal saline intravenously daily for 5 days

Based on this trial design, predict the completion outcome and termination type (if applicable).